PT-141: Sexual Health Peptide Guide

Most peptides target metabolism or tissue repair. PT-141 targets something nobody talks about in polite company: sexual function. It works through melanocortin receptors in the brain, not through blood flow like PDE5 inhibitors. That distinction matters a lot.

How PT-141 works

PT-141 (bremelanotide) is a synthetic analog of alpha-MSH (alpha-melanocyte-stimulating hormone). It binds to melanocortin-4 receptors (MC4R) in the hypothalamus. These receptors regulate sexual arousal at the central nervous system level.

The key distinction: PDE5 inhibitors (sildenafil, tadalafil) work by increasing blood flow to genital tissue. They're mechanical. If the desire isn't there, they don't create it. PT-141 works upstream, in the brain. It influences the desire itself by modulating dopaminergic pathways involved in sexual motivation.

This makes it relevant for people where the issue isn't blood flow but drive. Hypoactive sexual desire disorder (HSDD) was the primary indication in clinical trials.

Clinical data

The RECONNECT trials (Phase III, 2016-2018) studied bremelanotide in premenopausal women with HSDD. Over 1200 participants across two studies.

• Statistically significant increase in "satisfying sexual events" compared to placebo
• Improvement in sexual desire scores measured by the Female Sexual Function Index
• Effects were measurable within 30-60 minutes of administration

For men, earlier Phase II work showed improvements in erectile function, particularly in cases where PDE5 inhibitors had limited effect (suggesting the issue was central, not vascular).

Bremelanotide received FDA approval in 2019 for HSDD in premenopausal women under the brand name Vyleesi. The research compound (PT-141) is the same molecule.

Practical use

PT-141 is administered subcutaneously, typically 45-60 minutes before anticipated activity. The effect window is 2-6 hours, with peak effect around 1-2 hours post-injection.

Standard research dose: 1-2mg subcutaneously. The clinical trials used 1.75mg as the primary dose. Higher doses didn't improve efficacy but increased side effects.

[[PT-141|19]] comes in vial format. Reconstitute with bacteriostatic water. One vial provides multiple doses.

This is an on-demand peptide, not a daily protocol. Use as needed, not on a fixed schedule. The recommendation from trial data: no more than once every 24 hours, and no more than 8 doses per month.

Side effects

Nausea is the main one. About 40% of clinical trial participants reported it, usually mild and lasting 1-2 hours. Taking it on a partially full stomach helps.

Flushing (face and chest warmth/redness) in about 20%. Headache in about 10%. These are related to the melanocortin receptor activation and are generally transient.

One important note: PT-141 can temporarily raise blood pressure (by about 5-10 mmHg). If you have uncontrolled hypertension or cardiovascular concerns, discuss this with a doctor first.

Who this is for

If the issue is desire rather than mechanics. If PDE5 inhibitors work fine for function but don't address motivation. If you're interested in a central nervous system approach to sexual health research.

Check out [[PT-141|19]]. If you have questions about dosing or suitability, reach out to us.

This article is for educational purposes. Peptides are intended for research use. Consult a healthcare professional before starting any protocol.